CorMedix (CRMD) Income from Continuing Operations (2010 - 2025)
CorMedix (CRMD) reported Income from Continuing Operations of 11776859.0 for Q4 2025, down 187.47% on a YoY basis from 13464424.0 in Q4 2024, and down 110.85% sequentially from 108562980.0 in Q3 2025.
CorMedix (CRMD) Income from Continuing Operations (2010 - 2025) Analysis & Trends
CorMedix (CRMD) has 16 years of Income from Continuing Operations data on file, last reported at 11776859.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 187.47% year-over-year to 11776859.0; the trailing twelve-month figure through Dec 2025 stood at 137258000.0 (up 865.52% YoY), and the FY2025 full-year result was 137258000.0, up 865.52% from the prior year.
- Income from Continuing Operations retreated to 11776859.0 in Q4 2025, from 108562980.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 108562980.0 in Q3 2025 to a low of 17255239.0 in Q1 2021.
- A 5-year average of 101696.95 and a median of 8389158.5 in 2021 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 199.88% in 2021 and jumped 4002.28% in 2025, its largest moves.
- Tracing CRMD's Income from Continuing Operations over 5 years: stood at 9667173.0 in 2021, then grew by 15.08% to 8208951.0 in 2022, then tumbled by 79.73% to 14754029.0 in 2023, then jumped by 191.26% to 13464424.0 in 2024, then slumped by 187.47% to 11776859.0 in 2025.
- Business Quant data shows CRMD's Income from Continuing Operations at 11776859.0 in Q4 2025, 108562980.0 in Q3 2025, and 19827981.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,930.72 Bn | 1,930.66 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.36 Bn | 466.57 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 123.47 Bn | 116.22 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.00 Bn | 62.00 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.08 Bn | 50.89 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 205.99 Mn |
| 10 | CorMedix | 5.07 Mn | -150.13 Mn | 107.31 Mn | -11.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.78 Mn |
| Sep 30, 2025 | 108.56 Mn |
| Jun 30, 2025 | 19.83 Mn |
| Mar 31, 2025 | 20.64 Mn |
| Dec 31, 2024 | 13.46 Mn |
| Sep 30, 2024 | -2.78 Mn |
| Jun 30, 2024 | -14.15 Mn |
| Mar 31, 2024 | -14.47 Mn |
| Dec 31, 2023 | -14.75 Mn |
| Sep 30, 2023 | -9.74 Mn |
| Jun 30, 2023 | -11.27 Mn |
| Mar 31, 2023 | -10.57 Mn |
| Dec 31, 2022 | -8.21 Mn |
| Sep 30, 2022 | -6.85 Mn |
| Jun 30, 2022 | -7.60 Mn |
| Mar 31, 2022 | -8.16 Mn |
| Dec 31, 2021 | -9.67 Mn |
| Sep 30, 2021 | -8.57 Mn |
| Jun 30, 2021 | -4.63 Mn |
| Mar 31, 2021 | -17.26 Mn |